Would you offer adjuvant immune checkpoint therapy for a patient with resected mucosal melanoma with a tumor thickness >4.0 mm with negative LN involvement?

Topics: Melanoma/Skin Cancer • Medical Oncology

Answer from: Medical Oncologist at Academic Institution

Although adjuvant therapy is an option for patients with thick cutaneous melanomas, based on the results of the KEYNOTE-716 clinical trial (as well as CheckMate76K clinical trials), these trials limited accruals to cutaneous melanoma patients only. Thus, the efficacy of adjuvant immune checkpoint th...

Comments

Medical Oncologist at Onc San Antonio
Thank you Dr. @Kaur.

Related Questions